Breathe Well Live Well
Condition: Hypereosinophilic Syndrome
Interventions: Drug: Mepolizumab 300 mg; Drug: Placebo matching mepolizumab; Drug: Active OCS capsules (5 mg prednisolone or prednisone); Drug: Placebo matching OCS capsules
Sponsor: GlaxoSmithKline
Not yet recruiting – verified July 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
|
Clinical usefulness of mepolizumab in severe eosinophilic asthma
Dove Medical Press Abstract: Asthma is a chronic inflammatory disorder of the airways with variable clinical severity from very mild and occasional symptoms to recurrent critical exacerbations, at risk of fatal or near-fatal outcome, in a small percentage of patients … |
View full post on asthma – Google News
|
Benefit of mepolizumab for asthma not proven in trials
UPI.com Mepolizumab, sold as Nucala, was not compared fairly against other asthma treatments, raising questions as to whether it has benefits over other drugs already used for the condition, the German Institute for Quality and Efficiency in Health Care said … Mepolizumab in severe asthma: Added benefit not proven |
View full post on asthma – Google News
Condition: Asthma
Interventions: Drug: Mepolizumab 100mg SC; Drug: Albuterol/salbutamol MDIs; Drug: Omalizumab
Sponsor: GlaxoSmithKline
Not yet recruiting – verified January 2016
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Ledger Gazette |
FDA approves Mepolizumab for maintenance treatment of severe asthma
Ledger Gazette The US Food and Drug Administration has cleared use of Nucala (mepolizumab) in patients with severe asthma aged 12 years and older whose condition is driven by eosinophilic inflammation, offering patients access to the first and only approved biologic … Nucala approved to treat severe asthma |
View full post on asthma – Google News
Condition: Asthma
Interventions: Biological: Mepolizumab 100mg; Drug: Placebo
Sponsor: GlaxoSmithKline
Not yet recruiting – verified September 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Medscape |
CHMP Backs Mepolizumab for Severe Eosinophilic Asthma
Medscape The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval of mepolizumab (Nucala, GlaxoSmithKline) for add-on maintenance treatment in adults with severe refractory eosinophilic asthma, … EU regulator backs approval for GSK injectable asthma drug GlaxoSmithKline's asthma injection heads for EU approval Glaxo asthma drug clears key hurdle in Europe |
View full post on asthma – Google News
|
FDA panel backs approval of GSK's mepolizumab for severe asthma
ModernMedicine FDA's Pulmonary-Allergy Drugs Advisory Committee recently recommended approval of GlaxoSmithKline Plc's drug mepolizumab (Nucala) for severe asthma in patients aged 18 years and older. However, the panel voted 10 to 4 against approving the drug in … |
View full post on asthma – Google News
Medscape |
FDA Panel Backs Mepolizumab for Severe Eosinophilic Asthma
Medscape A typical characteristic of mild asthma is airway inflammation due to eosinophils, and this inflammation is closely associated with the risk for severe asthma exacerbations. Several products are approved for long-term maintenance treatment of asthma … FDA panel backs approval of GSK asthma drug in adults Asthma Drug Targeting IL-5 Wins Partial Backing From FDA Advisers UPDATE: Glaxo's (GSK) Severe Asthma Drug Mepolizumab Found Effective in … |
View full post on asthma – Google News
|
UPDATE: Glaxo's (GSK) Severe Asthma Drug Mepolizumab Found Effective in …
StreetInsider.com GlaxoSmithKline (NYSE: GSK) severe asthma drug, mepolizumab, is effective in adults, FDA panel says, according to Bloomberg. UPDATE – Last November, Glaxo announced that it filed regulatory submissions in the USA and Europe for mepolizumab for … |
View full post on asthma – Google News